Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Rasche

Showing results (91-100 of 170) with videos related to

Pageof 17
Sort By:
Nature Communications|August 3, 2022
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesLeo Rasche, Carolina Schinke, Francesco Maura, et al.
Haematologica|December 11, 2025
Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding responseAndrej Besse, Marianne Kraus, Tiberiu Totu, et al.
Blood|November 17, 2023
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapyJohannes Duell, Alexander M Leipold, Silke Appenzeller, et al.
Oncotarget|April 22, 2017
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myelomaCaleb K Stein, Charlotte Pawlyn, Shweta Chavan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 5, 2023
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone LymphomaJohannes Duell, Andreas K Buck, Philipp E Hartrampf, et al.
Iscience|September 2, 2025
Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-systemMax Mendez-Lopez, Andrej Besse, Christian Zuppinger, et al.
Cancers|April 27, 2024
Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter AnalysisGrzegorz Charliński, Maximilian Steinhardt, Leo Rasche, et al.
Haematologica|March 24, 2018
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myelomaFaith E Davies, Adam Rosenthal, Leo Rasche, et al.
Leukemia|January 31, 2023
Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myelomaAlexander M Leipold, Rudolf A Werner, Johannes Düll, et al.
Theranostics|August 2, 2019
Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?Leo Rasche, Manoj Kumar, Grant Gershner, et al.
Pageof 17

Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
Nature Communications|August 3, 2022
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory statesLeo Rasche, Carolina Schinke, Francesco Maura, et al.
Haematologica|December 11, 2025
Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding responseAndrej Besse, Marianne Kraus, Tiberiu Totu, et al.
Blood|November 17, 2023
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapyJohannes Duell, Alexander M Leipold, Silke Appenzeller, et al.
Oncotarget|April 22, 2017
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myelomaCaleb K Stein, Charlotte Pawlyn, Shweta Chavan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 5, 2023
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone LymphomaJohannes Duell, Andreas K Buck, Philipp E Hartrampf, et al.
Iscience|September 2, 2025
Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-systemMax Mendez-Lopez, Andrej Besse, Christian Zuppinger, et al.
Cancers|April 27, 2024
Outcomes of Modified Mayo Stage IIIa and IIIb Cardiac Light-Chain Amyloidosis: Real-World Experience in Clinical Characteristics and Treatment-67 Patients Multicenter AnalysisGrzegorz Charliński, Maximilian Steinhardt, Leo Rasche, et al.
Haematologica|March 24, 2018
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myelomaFaith E Davies, Adam Rosenthal, Leo Rasche, et al.
Leukemia|January 31, 2023
Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myelomaAlexander M Leipold, Rudolf A Werner, Johannes Düll, et al.
Theranostics|August 2, 2019
Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?Leo Rasche, Manoj Kumar, Grant Gershner, et al.
Pageof 17